• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Events

How to build a health commons approach to pandemic preparedness and response

16 January 2023, 2-4 PM Geneva

Geneva, Switzerland and online

Hybrid event, co-hosted by DNDi, UCL Institute for Innovation and Public Purpose, & Friends of the Independent Panel

Participation in-person at DNDi office in Geneva or online

In its May 2021 report, the Independent Panel for Pandemic Preparedness and Response (IPPPR) recommended a commons approach to research and development for pandemic tools, and several other groups have explored strategies for the effective sharing of knowledge and technologies for public health purpose.

The aim of this workshop is to start to identify the key elements of a collective framework to organize, finance, and coordinate health innovation by public and private sectors. It will discuss some of the latest economic thinking on collective ownership, explore current examples of managing collective knowledge to develop vaccines and treatments for PPR and help identify areas where policy makers can and should act to increase our collective capabilities for the development and equitable delivery of health technologies for pandemic preparedness and response.

The outcome of these discussions will inform policy discussions towards a new framework for pandemic tools, including a meeting entitled “Advancing a new approach to pandemic tools as common goods”, convened by the former Independent Panel co-chair Rt Hon Helen Clark at the Rockefeller Bellagio Centre on 14-16 February 2023.

Diagnostics, vaccines and therapeutics are critical to global pandemic preparedness and response (PPR), and ensuring equitable access to both the underlying knowledge technologies and products requires managing them other than as privately owned commodities.

Building a policy framework to foster more equitable system from R&D to access thus implies a form of collective investment, with shared ownership and clearly defined access rules developed collaboratively around a shared purpose, for instance public health or outbreak and pandemic control. While there has been much discussion around global public goods there has been less focus on how the evolving concepts of “the commons” and “common good approaches” could offer a promising policy framework around which to develop a more sustainable and equitable approach to PPR.

A critical aspect for outbreak response is the ability to rapidly generate effective diagnostics, treatments, and vaccines, and roll them out at the required scale where needed. One way for achieving rapid innovation is through adapting existing technology platforms to new health challenges, in particular for vaccines, or repurposing existing treatments.  Freedom to use knowledge and access to the technical knowhow with technology transfer as needed will be critical to increase our collective capacity to respond to outbreaks anywhere. Enabling such collective capacity could be achieved through a common good approach.

Clinical trials for new drugs or vaccines for PPR must happen as part of the epidemic control response. It is therefore important to establish, in advance, independent and public health-focused trial capacity to swiftly evaluate different interventions in a standardized, comparable, and transparent manner. A commons-based approach that stipulates user and access rights and responsibilities around clinical trial data generated through pre-established clinical trial platforms can enable conditioning access to the platform for developers, including private companies, to binding commitments about the further development, registration, availability, and access.

A collective approach requires the deliberate creation of appropriate legal, policy and institutional frameworks for collective ownership and governance outside the commercial realm, promoting access and user rights rather than exclusive ownership.

Watch recording

Agenda

Moderator: Spring Gombe, Partner and Principal, Public Affairs Practice, Market Access Africa

Introduction and framing

Rt Hon Helen Clark, former co-chair of The Independent Panel

Keynote – Health for All: From a public good to a common good approach

Professor Mariana Mazzucato, Founder and Director, Institute for Innovation and Public Purpose (IIPP), University College London, and Chair of the WHO Council on the Economics of Health for All

“Health for All: moving from market fixing public goods to market shaping around the common good”

Initiatives to deliver common goods for health

Technology sharing and managing collective knowledge within the WHO mRNA technology transfer Hub
Chan Park, General Counsel, Medicines Patent Pool
Knowledge sharing within the Moonshot consortium
Annette Von Delft, Translational Scientist, Centre for Medicines Discovery, University of Oxford
Using emerging technologies for improving NTDs diagnostics: Open Science principles applied to AI and local manufacturing for medical labs in Africa
Thomas Hervé Mboa Nkoudou, Researcher at CEIMIA and Founder of the Mboa Lab

Respondents:

  • Suerie Moon, Co-Director, Global Health Centre, Graduate Institute of International and Development Studies, and DNDi Board Member
  • Benjamin Coriat, En Communs, Université Paris Sorbonne
  • Sangeeta Shashikant, Legal Advisor, Coordinator Development and Intellectual Property Programme, Third World Network
  • Viviana Munoz Tellez, Coordinator, Health, Intellectual Property and Biodiversity Programme (HIPB), South Centre

Discussion

Closing remarks

  • Els Torreele, Friends of the Independent Panel and Institute for Innovation and Public Purpose
  • Luis Pizarro, Executive Director, DNDi

Other events

Loading...
20 May 2025

Geneva, Switzerland

Strengthening the global ecosystem for paediatric medicines: leadership, collaboration, and impact

21 May 2025

Geneva, Switzerland

Scaling impact: Climate & health solutions that drive change

7-10 May 2025

Amsterdam, The Netherlands

EASL Congress 2025

20-25 May 2025

Iguaçu Falls, Brazil

22nd ISHAM Congress

See all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License